These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53 related articles for article (PubMed ID: 7946067)
21. Specific locations of hydrophilic amino acids in constructed transmembrane ligands of the platelet-derived growth factor beta receptor. Freeman-Cook LL; Edwards AP; Dixon AM; Yates KE; Ely L; Engelman DM; Dimaio D J Mol Biol; 2005 Jan; 345(4):907-21. PubMed ID: 15588835 [TBL] [Abstract][Full Text] [Related]
22. Sequence-dependent oligomerization of the Neu transmembrane domain suggests inhibition of "conformational switching" by an oncogenic mutant. Beevers AJ; Damianoglou A; Oates J; Rodger A; Dixon AM Biochemistry; 2010 Apr; 49(13):2811-20. PubMed ID: 20180588 [TBL] [Abstract][Full Text] [Related]
23. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407 [TBL] [Abstract][Full Text] [Related]
24. Analysis of structure and activation of some receptor-type tyrosine kinase oncogenes. Shibuya M; Matsushime H; Yamazaki H; Wang LH; Fukui Y; Ueyama Y; Tamaoki N Princess Takamatsu Symp; 1986; 17():195-202. PubMed ID: 3455414 [TBL] [Abstract][Full Text] [Related]
25. Unique carboxyl-terminal sequences of wild type and alternatively spliced variant forms of transforming growth factor-alpha precursors mediate specific interactions with ErbB4 and ErbB2. Xu X; Kelleher KF; Liao J; Creek KE; Pirisi L Oncogene; 2000 Jun; 19(28):3172-81. PubMed ID: 10918572 [TBL] [Abstract][Full Text] [Related]
26. Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases. Mineev KS; Bocharov EV; Pustovalova YE; Bocharova OV; Chupin VV; Arseniev AS J Mol Biol; 2010 Jul; 400(2):231-43. PubMed ID: 20471394 [TBL] [Abstract][Full Text] [Related]
27. Structural implications of a Val-->Glu mutation in transmembrane peptides from the EGF receptor. Sharpe S; Grant CW; Barber KR; Giusti J; Morrow MR Biophys J; 2001 Dec; 81(6):3231-9. PubMed ID: 11720988 [TBL] [Abstract][Full Text] [Related]
28. Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. Samanta A; LeVea CM; Dougall WC; Qian X; Greene MI Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1711-5. PubMed ID: 7907421 [TBL] [Abstract][Full Text] [Related]
29. The proto-oncogene c-ros codes for a transmembrane tyrosine protein kinase sharing sequence and structural homology with sevenless protein of Drosophila melanogaster. Chen JM; Heller D; Poon B; Kang L; Wang LH Oncogene; 1991 Feb; 6(2):257-64. PubMed ID: 1900358 [TBL] [Abstract][Full Text] [Related]
30. Characterization of an angiosarcoma-inducing mutation in the erbB oncogene. Robinson HL; Tracy SE; Nair N; Taglienti-Sian C; Gamett DC Oncogene; 1992 Oct; 7(10):2025-30. PubMed ID: 1408143 [TBL] [Abstract][Full Text] [Related]
31. Altered ligand dissociation rates in thyrotropin-releasing hormone receptors mutated in glutamine 105 of transmembrane helix III. del Camino D; Barros F; Pardo LA; de la Peña P Biochemistry; 1997 Mar; 36(11):3308-18. PubMed ID: 9116009 [TBL] [Abstract][Full Text] [Related]
32. [A turning point in the knowledge of the structure-function-activity relations of elastin]. Alix AJ J Soc Biol; 2001; 195(2):181-93. PubMed ID: 11727705 [TBL] [Abstract][Full Text] [Related]
33. Characterization of a new allele of the human ERBB2 gene by allele-specific competition hybridization. Ehsani A; Low J; Wallace RB; Wu AM Genomics; 1993 Feb; 15(2):426-9. PubMed ID: 8095488 [TBL] [Abstract][Full Text] [Related]
34. Conformation of the transmembrane domain of the epidermal growth factor receptor. Brandt-Rauf PW; Monaco R; Pincus MR J Protein Chem; 1994 Feb; 13(2):227-31. PubMed ID: 7914727 [TBL] [Abstract][Full Text] [Related]
35. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Trowe T; Boukouvala S; Calkins K; Cutler RE; Fong R; Funke R; Gendreau SB; Kim YD; Miller N; Woolfrey JR; Vysotskaia V; Yang JP; Gerritsen ME; Matthews DJ; Lamb P; Heuer TS Clin Cancer Res; 2008 Apr; 14(8):2465-75. PubMed ID: 18413839 [TBL] [Abstract][Full Text] [Related]
36. Structure prediction of the dimeric neu/ErbB-2 transmembrane domain from multi-nanosecond molecular dynamics simulations. Sajot N; Genest M Eur Biophys J; 2000; 28(8):648-62. PubMed ID: 10663532 [TBL] [Abstract][Full Text] [Related]
37. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. Penuel E; Akita RW; Sliwkowski MX J Biol Chem; 2002 Aug; 277(32):28468-73. PubMed ID: 12000754 [TBL] [Abstract][Full Text] [Related]
38. Aberrant c-erbB2 expression in cell clusters overlying focally disrupted breast myoepithelial cell layers: a trigger or sign for emergence of more aggressive cell clones? Zhang X; Hashemi SS; Yousefi M; Ni J; Wang Q; Gao L; Gong P; Gao C; Sheng J; Mason J; Man YG Int J Biol Sci; 2008 Aug; 4(5):259-69. PubMed ID: 18726004 [TBL] [Abstract][Full Text] [Related]
39. The transmembrane domain of Neu in a lipid bilayer: molecular dynamics simulations. van der Ende BM; Sharom FJ; Davis JH Eur Biophys J; 2004 Nov; 33(7):596-610. PubMed ID: 15197512 [TBL] [Abstract][Full Text] [Related]
40. Conformation of the transmembrane domain of the c-erbB-2 oncogene-encoded protein in its monomeric and dimeric states. Brandt-Rauf PW; Pincus MR; Monaco R J Protein Chem; 1995 Jan; 14(1):33-40. PubMed ID: 7779261 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]